CSL Behring’s Broadmeadows Plasma Facility Wins Prestigious 2025 ISPE Facility of the Year Award for Pharma 4.0 Innovation CSL Behring has earned global recognition for its trailblazing approach to pharmaceutical…
Gilead and Kite Set to Showcase Transformative Oncology Data at 2025 ASCO and EHA Conferences, Highlighting Advances in Breast Cancer, Multiple Myeloma, and Glioblastoma Gilead Sciences,and its Kite subsidiary are…
Merck’s KEYTRUDA-Based Regimen Achieves Major Milestone in Phase 3 KEYNOTE-B96 Trial for Platinum-Resistant Ovarian Cancer Merck & Co., Inc. (NYSE: MRK), operating as MSD outside the United States and Canada,…
GSK Acquires Phase III-Ready Efimosfermin for $1.2 Billion in Bid to Transform Steatotic Liver Disease Treatment GSK has announced a major strategic acquisition in the field of hepatology, entering into…
FDA Approves Merck’s WELIREG® (belzutifan) for Advanced Pheochromocytoma and Paraganglioma in Patients 12 Years and Older, Marking a New Era in Treatment of Rare Neuroendocrine Tumors Merck, known as MSD…
AbbVie and ADARx Partner to Advance Next-Generation siRNA Therapies Across Neuroscience, Immunology, and Oncology in Multibillion-Dollar Collaboration AbbVie, a global biopharmaceutical leader known for its portfolio of therapies in immunology,…
AbbVie Gains First Solid Tumor FDA Approval With EMRELIS™ for High c-Met Overexpressing Advanced NSCLC AbbVie has achieved a key milestone in its oncology pipeline with the announcement that the…
Novo Nordisk and Septerna Forge $2.2 Billion Global Alliance to Develop Oral Small Molecule Therapies for Obesity and Cardiometabolic Diseases In a significant expansion of its research and development pipeline,…
WHO Establishes Expert Surgical Sub-Group to Develop Global Guidelines for Caesarean Section Practices Caesarean section, often referred to as C-section, has become the most common major abdominal surgery performed across…
Sarepta’s ELEVIDYS Gene Therapy Gains Landmark Approval in Japan for Duchenne Muscular Dystrophy Sarepta Therapeutics, a biotechnology leader in precision genetic medicine for rare diseases, has announced a significant regulatory…
Legend Biotech Reports Strong First Quarter 2025 Performance and Strategic Milestones as CARVYKTI® Continues to Lead in Multiple Myeloma Legend Biotech Corporation, a global frontrunner in the field of cell…
WuXi Biologics Ireland: Pioneering Sustainable Biomanufacturing Through Purpose-Driven Innovation In an era where sustainability has become a defining metric of corporate integrity and resilience, WuXi Biologics Ireland stands out as…